Stay updated on Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page.

Latest updates to the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe page revision tag was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check40 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedShow glossary feature has been added to the page, and the page now displays the label 'Last Update Submitted that Met QC Criteria' along with revision 'v3.4.0'. The previous label 'Last Update Submitted that met QC Criteria', the 'No FEAR Act data' entry, and the prior revision 'v3.3.4' were updated to reflect capitalization and version updates.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page's revision indicator was updated from v3.3.3 to v3.3.4. This appears to be a metadata update with no visible changes to study content.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded a Locations section showing Houston, Texas as a study site. The update also updates the revision from v3.3.2 to v3.3.3 and removes the old 'Texas Locations' header as well as the HHS Vulnerability Disclosure link.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Elbasvir/Grazoprevir Clinical Trial page.